Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer
Abstract Introduction Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plas...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2010-05, Vol.68 (2), p.283-287 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 287 |
|---|---|
| container_issue | 2 |
| container_start_page | 283 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 68 |
| creator | van der Drift, Miep A Hol, Bernard E.A Klaassen, Corné H.W Prinsen, Clemens F.M van Aarssen, Yvonne A.W.G Donders, Rogier van der Stappen, Jos W.J Dekhuijzen, P.N. Richard van der Heijden, Henricus F.M Thunnissen, Frederik B.J.M |
| description | Abstract Introduction Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients. Methods 46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human β-globin gene. Survival analysis was performed using the Kaplan–Meier method and compared with a Cox-regression analysis. Results The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found. Conclusion In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients. |
| doi_str_mv | 10.1016/j.lungcan.2009.06.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733839326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500209003778</els_id><sourcerecordid>733839326</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-c396d4db379be590c4c21f1c54581eed8b383398b1728028ad13177378fbc3843</originalsourceid><addsrcrecordid>eNqFksFu1DAQhi0EotvCI4B8QZwSZuxNbF9A1UKhUtUegCuW4zgrL1mn2Emkvj0OG4HEpQfbl29mfn8aQl4hlAhYvzuU_RT21oSSAagS6hIYPiEblIIVknP2lGwyp4oKgJ2R85QOACgQ1HNyhqrmTPB6Q37sfLRTb0Yf9vTj7SX1iRoahlD4MJvkZ0fv47APQxq9pZ2x4xBpl0-a4uxn01Mf_uDpaPqeWpevJRjNyayLL8izzvTJvVzfC_L96tO33Zfi5u7z9e7yprAVVmNhuarbbdtwoRpXKbBby7BDW20ric61suH5S0o2KJgEJk2LHIXgQnaN5XLLL8jbU98c9tfk0qiPPi1hTHDDlLTguYHirM5kdSJtHFKKrtP30R9NfNAIejGrD3o1qxezGmqdzea61-uEqTm69l_VqjIDb1bAJGv6LmYBPv3lGKuRAS6NPpw4l33M3kWdrHdZVuujs6NuB_9olPf_dbC9Dz4P_ekeXDoMUwxZtkadmAb9dVmDZQtAAXAhJP8Nvv2trQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733839326</pqid></control><display><type>article</type><title>Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Drift, Miep A ; Hol, Bernard E.A ; Klaassen, Corné H.W ; Prinsen, Clemens F.M ; van Aarssen, Yvonne A.W.G ; Donders, Rogier ; van der Stappen, Jos W.J ; Dekhuijzen, P.N. Richard ; van der Heijden, Henricus F.M ; Thunnissen, Frederik B.J.M</creator><creatorcontrib>van der Drift, Miep A ; Hol, Bernard E.A ; Klaassen, Corné H.W ; Prinsen, Clemens F.M ; van Aarssen, Yvonne A.W.G ; Donders, Rogier ; van der Stappen, Jos W.J ; Dekhuijzen, P.N. Richard ; van der Heijden, Henricus F.M ; Thunnissen, Frederik B.J.M</creatorcontrib><description>Abstract Introduction Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients. Methods 46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human β-globin gene. Survival analysis was performed using the Kaplan–Meier method and compared with a Cox-regression analysis. Results The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found. Conclusion In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2009.06.021</identifier><identifier>PMID: 19632736</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Oxford: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - physiopathology ; Carcinoma, Non-Small-Cell Lung - therapy ; Circulating DNA ; DNA - blood ; DNA, Neoplasm - blood ; Female ; Follow-Up Studies ; Hematology, Oncology and Palliative Medicine ; Humans ; Inflammation ; Lung Neoplasms - blood ; Lung Neoplasms - diagnosis ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - physiopathology ; Lung Neoplasms - therapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Non-small cell lung cancer ; Plasma ; Pneumology ; Prognosis ; Prognostic factor ; Prospective Studies ; Pulmonary/Respiratory ; Survival ; Survival Analysis ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2010-05, Vol.68 (2), p.283-287</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2009 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-c396d4db379be590c4c21f1c54581eed8b383398b1728028ad13177378fbc3843</citedby><cites>FETCH-LOGICAL-c515t-c396d4db379be590c4c21f1c54581eed8b383398b1728028ad13177378fbc3843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169500209003778$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22612011$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19632736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Drift, Miep A</creatorcontrib><creatorcontrib>Hol, Bernard E.A</creatorcontrib><creatorcontrib>Klaassen, Corné H.W</creatorcontrib><creatorcontrib>Prinsen, Clemens F.M</creatorcontrib><creatorcontrib>van Aarssen, Yvonne A.W.G</creatorcontrib><creatorcontrib>Donders, Rogier</creatorcontrib><creatorcontrib>van der Stappen, Jos W.J</creatorcontrib><creatorcontrib>Dekhuijzen, P.N. Richard</creatorcontrib><creatorcontrib>van der Heijden, Henricus F.M</creatorcontrib><creatorcontrib>Thunnissen, Frederik B.J.M</creatorcontrib><title>Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Abstract Introduction Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients. Methods 46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human β-globin gene. Survival analysis was performed using the Kaplan–Meier method and compared with a Cox-regression analysis. Results The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found. Conclusion In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - physiopathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Circulating DNA</subject><subject>DNA - blood</subject><subject>DNA, Neoplasm - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Non-small cell lung cancer</subject><subject>Plasma</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Prognostic factor</subject><subject>Prospective Studies</subject><subject>Pulmonary/Respiratory</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhi0EotvCI4B8QZwSZuxNbF9A1UKhUtUegCuW4zgrL1mn2Emkvj0OG4HEpQfbl29mfn8aQl4hlAhYvzuU_RT21oSSAagS6hIYPiEblIIVknP2lGwyp4oKgJ2R85QOACgQ1HNyhqrmTPB6Q37sfLRTb0Yf9vTj7SX1iRoahlD4MJvkZ0fv47APQxq9pZ2x4xBpl0-a4uxn01Mf_uDpaPqeWpevJRjNyayLL8izzvTJvVzfC_L96tO33Zfi5u7z9e7yprAVVmNhuarbbdtwoRpXKbBby7BDW20ric61suH5S0o2KJgEJk2LHIXgQnaN5XLLL8jbU98c9tfk0qiPPi1hTHDDlLTguYHirM5kdSJtHFKKrtP30R9NfNAIejGrD3o1qxezGmqdzea61-uEqTm69l_VqjIDb1bAJGv6LmYBPv3lGKuRAS6NPpw4l33M3kWdrHdZVuujs6NuB_9olPf_dbC9Dz4P_ekeXDoMUwxZtkadmAb9dVmDZQtAAXAhJP8Nvv2trQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>van der Drift, Miep A</creator><creator>Hol, Bernard E.A</creator><creator>Klaassen, Corné H.W</creator><creator>Prinsen, Clemens F.M</creator><creator>van Aarssen, Yvonne A.W.G</creator><creator>Donders, Rogier</creator><creator>van der Stappen, Jos W.J</creator><creator>Dekhuijzen, P.N. Richard</creator><creator>van der Heijden, Henricus F.M</creator><creator>Thunnissen, Frederik B.J.M</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer</title><author>van der Drift, Miep A ; Hol, Bernard E.A ; Klaassen, Corné H.W ; Prinsen, Clemens F.M ; van Aarssen, Yvonne A.W.G ; Donders, Rogier ; van der Stappen, Jos W.J ; Dekhuijzen, P.N. Richard ; van der Heijden, Henricus F.M ; Thunnissen, Frederik B.J.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-c396d4db379be590c4c21f1c54581eed8b383398b1728028ad13177378fbc3843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - physiopathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Circulating DNA</topic><topic>DNA - blood</topic><topic>DNA, Neoplasm - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Non-small cell lung cancer</topic><topic>Plasma</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Prognostic factor</topic><topic>Prospective Studies</topic><topic>Pulmonary/Respiratory</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Drift, Miep A</creatorcontrib><creatorcontrib>Hol, Bernard E.A</creatorcontrib><creatorcontrib>Klaassen, Corné H.W</creatorcontrib><creatorcontrib>Prinsen, Clemens F.M</creatorcontrib><creatorcontrib>van Aarssen, Yvonne A.W.G</creatorcontrib><creatorcontrib>Donders, Rogier</creatorcontrib><creatorcontrib>van der Stappen, Jos W.J</creatorcontrib><creatorcontrib>Dekhuijzen, P.N. Richard</creatorcontrib><creatorcontrib>van der Heijden, Henricus F.M</creatorcontrib><creatorcontrib>Thunnissen, Frederik B.J.M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Drift, Miep A</au><au>Hol, Bernard E.A</au><au>Klaassen, Corné H.W</au><au>Prinsen, Clemens F.M</au><au>van Aarssen, Yvonne A.W.G</au><au>Donders, Rogier</au><au>van der Stappen, Jos W.J</au><au>Dekhuijzen, P.N. Richard</au><au>van der Heijden, Henricus F.M</au><au>Thunnissen, Frederik B.J.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>68</volume><issue>2</issue><spage>283</spage><epage>287</epage><pages>283-287</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Abstract Introduction Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients. Methods 46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human β-globin gene. Survival analysis was performed using the Kaplan–Meier method and compared with a Cox-regression analysis. Results The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found. Conclusion In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients.</abstract><cop>Oxford</cop><pub>Elsevier Ireland Ltd</pub><pmid>19632736</pmid><doi>10.1016/j.lungcan.2009.06.021</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2010-05, Vol.68 (2), p.283-287 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733839326 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - physiopathology Carcinoma, Non-Small-Cell Lung - therapy Circulating DNA DNA - blood DNA, Neoplasm - blood Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Inflammation Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - physiopathology Lung Neoplasms - therapy Male Medical sciences Middle Aged Neoplasm Staging Non-small cell lung cancer Plasma Pneumology Prognosis Prognostic factor Prospective Studies Pulmonary/Respiratory Survival Survival Analysis Tumors Tumors of the respiratory system and mediastinum |
| title | Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A27%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20DNA%20is%20a%20non-invasive%20prognostic%20factor%20for%20survival%20in%20non-small%20cell%20lung%20cancer&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=van%20der%20Drift,%20Miep%20A&rft.date=2010-05-01&rft.volume=68&rft.issue=2&rft.spage=283&rft.epage=287&rft.pages=283-287&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2009.06.021&rft_dat=%3Cproquest_cross%3E733839326%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733839326&rft_id=info:pmid/19632736&rft_els_id=S0169500209003778&rfr_iscdi=true |